Acknowledgments
The authors thank members of the National Centre for Infections in Cancer Clinical trials team (Department of Infectious Diseases), Ms Rebecca Blackwood and Ms Trish Joyce (Department of Hematology) and Ms Gail Rowan (Department of Pharmacy) for their help in the conduct of this study.
Author contributions
Study Design: V.G.H, B.W.T, M.S., M.Y., K.K, O.N., J.F.S, V.W. Data Analysis: V.G.H, B.W.T. Data collection: V.G.H, C.L. Manuscript Writing: All authors.
Disclosure statement
BWT has been on the advisory board for Moderna, Takeda, and CSL-Behring and received research funding from MSD, Sanofi, and Seqirus. MAS has been on data safety monitoring and adjudication committees for Cidara, Roche, and Pfizer. She has received research funding from Gilead Sciences, Merck, F2G and sat on advisory boards for Gilead Sciences, F2G, Cidara, Takeda, and Merck. JFS has been on the advisory board for AbbVie, Astra Zeneca, Beigene, BMS, Gilead, Roche, Janssen, and scientific advisory board for Genor Bio. He has received research funding from AbbVie, BMS, and Roche. He has been part of the speakers’ bureau for AbbVie, BMS, and Roche. He is a consultant and has given expert testimony to TG Therapeutics. All other authors have no conflicts of interest to disclose.
Data availability statement
De-identified data that support the findings of this study are available for ethics approved studies from the corresponding author upon reasonable request. Data transfer agreement will be required.